Histogen Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Susan Knudson

Chief executive officer

US$681.2k

Total compensation

CEO salary percentage68.4%
CEO tenure3.7yrs
CEO ownershipn/a
Management average tenureno data
Board average tenure9.9yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Susan Knudson's remuneration changed compared to Histogen's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2023n/an/a

-US$12m

Jun 30 2023n/an/a

-US$12m

Mar 31 2023n/an/a

-US$14m

Dec 31 2022US$681kUS$466k

-US$11m

Sep 30 2022n/an/a

-US$11m

Jun 30 2022n/an/a

-US$12m

Mar 31 2022n/an/a

-US$11m

Dec 31 2021US$539kUS$385k

-US$15m

Sep 30 2021n/an/a

-US$15m

Jun 30 2021n/an/a

-US$15m

Mar 31 2021n/an/a

-US$21m

Dec 31 2020US$767kUS$212k

-US$19m

Compensation vs Market: Susan's total compensation ($USD681.24K) is above average for companies of similar size in the German market ($USD409.16K).

Compensation vs Earnings: Susan's compensation has increased whilst the company is unprofitable.


CEO

Susan Knudson (59 yo)

3.7yrs

Tenure

US$681,237

Compensation

Ms. Susan A. Knudson is Chief Financial Officer of Histogen Inc. since May 2020 and serves as its Chief Compliance Officer and Corporate Secretary and serves as its Chief Operations Officer since March 10,...


Board Members

NamePositionTenureCompensationOwnership
Daniel Kisner
Independent Non-Executive Chairman9.9yrsUS$52.70k0.0011%
€ 14.6
Neil Sadick
Member of the Scientific Advisory Board13.5yrsno datano data
Craig Ziering
Member of Scientific Advisory Boardno datano datano data
Susan Windham-Bannister
Independent Director2.8yrsUS$57.70k0%
€ 0
Rochelle Fuhrmann
Independent Director2.8yrsUS$58.81k0%
€ 0
Dale DeVore
Member of the Scientific Advisory Boardno datano datano data
David Crean
Independent Director5.8yrsUS$85.24k0%
€ 0
Jonathan Jackson
Independent Director13.1yrsUS$51.05k2.76%
€ 36.7k
David Easter
Member of Scientific Advisory Boardno datano datano data
Brian Satz
Independent Director11.2yrsUS$56.70k0.0017%
€ 22.5

9.9yrs

Average Tenure

61yo

Average Age

Experienced Board: CPH's board of directors are considered experienced (9.9 years average tenure).


Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/01/10 02:17
End of Day Share Price 2023/10/13 00:00
Earnings2023/09/30
Annual Earnings2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Histogen Inc. is covered by 2 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
John NewmanCanaccord Genuity
Douglas TsaoH.C. Wainwright & Co.